JP2019521167A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521167A5
JP2019521167A5 JP2019502675A JP2019502675A JP2019521167A5 JP 2019521167 A5 JP2019521167 A5 JP 2019521167A5 JP 2019502675 A JP2019502675 A JP 2019502675A JP 2019502675 A JP2019502675 A JP 2019502675A JP 2019521167 A5 JP2019521167 A5 JP 2019521167A5
Authority
JP
Japan
Prior art keywords
nicotinamide
amino
phenyl
azabicyclo
hexan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019502675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521167A (ja
JP7030776B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/093385 external-priority patent/WO2018014829A1/en
Publication of JP2019521167A publication Critical patent/JP2019521167A/ja
Publication of JP2019521167A5 publication Critical patent/JP2019521167A5/ja
Priority to JP2022025894A priority Critical patent/JP7253086B2/ja
Application granted granted Critical
Publication of JP7030776B2 publication Critical patent/JP7030776B2/ja
Priority to JP2023048083A priority patent/JP7584553B2/ja
Priority to JP2024193634A priority patent/JP7834830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019502675A 2016-07-20 2017-07-18 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用 Active JP7030776B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022025894A JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2023048083A JP7584553B2 (ja) 2016-07-20 2023-03-24 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2024193634A JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
US62/364,620 2016-07-20
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022025894A Division JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Publications (3)

Publication Number Publication Date
JP2019521167A JP2019521167A (ja) 2019-07-25
JP2019521167A5 true JP2019521167A5 (https=) 2020-08-27
JP7030776B2 JP7030776B2 (ja) 2022-03-07

Family

ID=60991950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502675A Active JP7030776B2 (ja) 2016-07-20 2017-07-18 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2022025894A Active JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2023048083A Active JP7584553B2 (ja) 2016-07-20 2023-03-24 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2024193634A Active JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022025894A Active JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2023048083A Active JP7584553B2 (ja) 2016-07-20 2023-03-24 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2024193634A Active JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Country Status (25)

Country Link
US (3) US10710980B2 (https=)
EP (3) EP3487851B1 (https=)
JP (4) JP7030776B2 (https=)
KR (7) KR20240155367A (https=)
CN (2) CN109641871B (https=)
AR (1) AR109108A1 (https=)
AU (5) AU2017298187B2 (https=)
CY (1) CY1124967T1 (https=)
DK (2) DK3487851T3 (https=)
EA (2) EA037520B1 (https=)
ES (2) ES2984746T3 (https=)
FI (1) FI3971177T3 (https=)
HR (2) HRP20241015T1 (https=)
HU (2) HUE067992T2 (https=)
LT (2) LT3487851T (https=)
MX (2) MX388518B (https=)
PL (2) PL3971177T3 (https=)
PT (2) PT3971177T (https=)
RS (2) RS66041B1 (https=)
RU (1) RU2747318C2 (https=)
SI (2) SI3487851T1 (https=)
SM (2) SMT202100723T1 (https=)
TW (5) TWI851226B (https=)
UY (1) UY37331A (https=)
WO (1) WO2018014829A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10710980B2 (en) * 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのalk2阻害剤
KR102913358B1 (ko) * 2020-10-29 2026-01-14 주식회사 엘지화학 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN116478145B (zh) * 2022-04-13 2024-02-02 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
KR950704485A (ko) 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1623216A2 (en) 2003-04-11 2006-02-08 SGX Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
CA2567935C (en) 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2649770C (en) 2006-04-18 2017-08-15 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop)
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008033408A2 (en) 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Bmpシグナル伝達経路のインヒビター
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012161877A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
EP2753605B1 (en) 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
WO2014138088A1 (en) * 2013-03-04 2014-09-12 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
BR112017015273A2 (pt) 2015-01-20 2018-01-09 Merial Inc. compostos e composições antihelmínticos e método de utilizações dos mesmos
ES2799300T3 (es) 2015-08-31 2020-12-16 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como fármacos terapéuticos
US10710980B2 (en) 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
WO2018017635A1 (en) 2016-07-20 2018-01-25 Cavendish Kinetics, Inc Method for tuning an antenna with a dvc
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Similar Documents

Publication Publication Date Title
JP2019521167A5 (https=)
JP6218260B2 (ja) Jak阻害剤としてのアミノピリミジニル化合物
RU2019104609A (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
CN116323623B (zh) 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
AU2014291711B2 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
AU2014364744B2 (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
JP5667684B2 (ja) 関節炎の治療方法
JP2010508338A5 (https=)
US10214537B2 (en) Bicyclic heteroaryl amine compounds
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
US10023576B2 (en) Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
RU2017135520A (ru) Бициклические производные хиназолинона
RU2012126987A (ru) Спироиндолциклопропаниндолиноны в качестве модуляторов амрк
CN101605540A (zh) 使用mek抑制剂的方法
WO2019224773A1 (en) Heterocyclic amides as rip1 kinase inhibitors
JP2011524363A (ja) ヒスタミンh4受容体のジアミノピリジン、ピリミジン、及びピリダジンモジュレーター
AU2021242143B2 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
JP2018522929A5 (https=)
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
BR112019010164A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar aterosclerose, esteatose hepática, aterosclerose, diabetes mellitus tipo 2, obesidade, hiperlipidemia ou hipercolesterolemia.
JP2018515489A5 (https=)
JP2018505145A5 (https=)
CA3246382A1 (en) SMALL MOLECULES INHIBITING MEMBERS OF THE TEAD FAMILY (TEA DOMAIN)
RU2024125208A (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2